Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

Lancet

Volumn 351, Issue 9119, 1998, Pages 1881-1883

  Carr, Andrew ^a,b   Samaras, Katherine ^b   Chisholm, Donald J ^b   Cooper, David A ^c  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHYLOMICRON; CYTOCHROME P450; ESTROGEN; LOW DENSITY LIPOPROTEIN RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROTEINASE INHIBITOR; RETINOIC ACID; RETINOIC ACID BINDING PROTEIN; TRIACYLGLYCEROL;

ADIPOCYTE; APOPTOSIS; ARTICLE; BREAST HYPERTROPHY; CELL DIFFERENTIATION; DIABETES MELLITUS; ENZYME BINDING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0032551258     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)03391-1     Document Type: Note

References (25)

1. 1 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-58.
2. 2 Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-39.
3. 3 Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-75.
4. 4 Kerry I, Bernard L, de Truchis P, Perronne C. Hypertrophy of the breast in a patient treated with indinavir. Clin Infect Dis 1997; 25: 937-38.
5. 5 Lo JC, Mulligna K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998; 351: 867-70.
6. 6 Navia MA, Fitzgerald PMD, McKeever BM, et al. Three dimensional structure of aspartyl protease from human immunodeficiency virus (HIV-1). Nature 1989; 337: 615-20.
7. 7 Li E, Norris AW. Structure/function of cytoplasmic vitamin A-binding proteins. Annu Rev Nutr 1996; 16: 205-34.
8. 8 Napoli JL. Retinoic acid biosynthesis and metabolism. FASEB J 1996; 10: 993-1001.
9. 9 Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-54.
10. 10 Pfahl M, Chytil F. Regulation of metabolism by retinoic acid and its receptors. Annu Rev Nutr 1996; 16: 257-83.
11. 11 Prins JB, O'Rahilly S. Regulation of adipose cell number in man. Clin Sci 1997; 92: 3-11.
12. 12 Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994; 79: 1147-56.
13. 13 Adams M, Montague C, Prins JB, et al. Activators of peroxisome proliferator activated receptor type gamma have depot-specific effects on human adipocyte differentiation. J Clin Invest 1997; 100: 3149-53.
14. 14 Mukherjee R, Davies PJA, Crombie DL, et al. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997; 386: 407-10.
15. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995; 83: 803-12.
16. 16 Thompson JR, Bratt JM, Banaszak LJ. Crystal structure of cellular retinoic acid binding protein I shows increased access to the binding activity due to formation of an intermolecular beta-sheet. J Molec Biol 1995; 252: 433-36.
17. 17 Beisiegel U, Weber W, Ihrke G, Herz J, Stanley KK. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989; 341: 162-64.
18. 18 Willnow TE, Sheng Z, Ishibashi S, Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science 1994; 264: 1471-74.
19. 19 Herz J. The LDL-receptor-related protein-portrait of a multifunctional receptor. Curr Opin Lipidol 1993; 4: 107-13.
20. 20 Samaras K, Campbell LV. The non-genetics determinants of central adiposity. Int J Obesity 1997; 21: 839-45.
21. 21 Despres J-P, Lemieux S, Lamarche B, et al. The insulin-resistance-dysipidemic syndrome: contributioin of visceral obesity and therapeutic implications. Int J Obesity 1995; 19: S76-86.
22. 22 Randle PJ, Garland PB, Hales CN, Newholme EA. The fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; i: 785-89.
23. 23 Jenkins AB, Storlien LH, Chisholm DJ, Kraegen EW. Effects of nonesterified fatty acid availability on tissue specific glucose utilisation in rats in vivo. J Clin Invest 1988; 82: 293-99.
24. 24 Kraegen EW, Carey DPG, Campbell LV. Effects of lipids on blood glucose regulation and insulin action. In: Draznin E, Rizza R, eds. Clinical research in diabetes and obesity, part I: methods, assessment, and metabolic regulation. Humana Press Inc Totowa, NJ, USA, 1997: 305-20.
25. 25 Decks SG, Smith M, Holodny M, Kahn JO. HIV-1 protease inhibitors: a review for clinicians. JAMA 1997; 277: 145-53.